RE:HmmmmmmThe new BPH application is quite positive as it adds another market vertical to use the technology and thus more potential patients=more potential revenue.
People are still skittish about the stock because the burn remains quite high and there are only now starting to get revenue traction (still very early stage with some risk to a phase II trial). That being said I think they are at a nice pivot point where revenues are starting to climb, all patients will have been recruited for the trial and results will likely start coming out the beginning of next year. If things start looking positive for the trial (which I believe it will be due to the positive treatments to date) that leads to FDA approval and a huge market for revenue ramp up in the US... IMO this will lead to a buyout (most companies get bought out around the phase II approval as the tech has been significantly de-risked and the large pharma or pharma tech buyer would just add this product to its other product lines and sell through its already established sales channels.
Best of luck.